The tissue factor-factor VIIa complex: Procoagulant activity, regulation, and multitasking

Journal of Thrombosis and Haemostasis

Volumn 5, Issue 6, 2007, Pages 1097-1105

  Monroe, Dougal M ^a   Key, N S ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Activated factor VII; Coagulation; Tissue factor

Indexed keywords

BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 7A THROMBOPLASTIN COMPLEX; POLYPHOSPHATE; PROCOAGULANT; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG;

BLOOD CLOTTING; CELL INTERACTION; COMPLEX FORMATION; HEMOSTASIS; HUMAN; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; THROMBOGENESIS; THROMBOSIS;

BLOOD COAGULATION; FACTOR VIIA; HEMOSTASIS; HUMANS; INFLAMMATION; LIPOPROTEINS; MODELS, MOLECULAR; MULTIPROTEIN COMPLEXES; PROTEIN PROCESSING, POST-TRANSLATIONAL; SIGNAL TRANSDUCTION; SOLUBILITY; THROMBOPLASTIN; THROMBOSIS;

EID: 34250158455     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2007.02435.x     Document Type: Review

References (119)

1. Mackman N. Role of tissue factor in hemostasis and thrombosis. Blood Cells Mol Dis 2006; 36: 104-7.
2. Pyo RT, Sato Y, Mackman N, Taubman MB. Mice deficient in tissue factor demonstrate attenuated intimal hyperplasia in response to vascular injury and decreased smooth muscle cell migration. Thromb Haemost 2004; 92: 451-8.
3. Carmeliet P, Mackman N, Moons L, Luther T, Gressens P, Van Vlaenderen I, Demunck H, Kasper M, Breier G, Evrard P, Muller M, Risau W, Edgington T, Collen D. Role of tissue factor in embryonic blood vessel development. Nature 1996; 383: 73-5.
4. Rak J, Milsom C, May L, Klement P, Yu J. Tissue factor in cancer and angiogenesis: The molecular link between genetic tumor progression, tumor neovascularization, and cancer coagulopathy. Semin Thromb Hemost 2006; 32: 54-70.
5. Spek CA. Tissue factor: From 'just one of the coagulation factors'to a major player in physiology. Blood Coagul Fibrinolysis 2004; 15 (Suppl. 1): S3-10.
6. Giesen PL, Rauch U, Bohrmann B, Kling D, Roque M, Fallon JT, Badimon JJ, Himber J, Riederer MA, Nemerson Y. Blood-borne tissue factor: Another view of thrombosis. Proc Natl Acad Sci USA 1999; 96: 2311-5.
7. Tutar E, Ozcan M, Kilickap M, Gulec S, Aras O, Pamir G, Oral D, Dandelet L, Key NS. Elevated whole-blood tissue factor procoagulant activity as a marker of restenosis after percutaneous transluminal coronary angioplasty and stent implantation. Circulation 2003; 108: 1581-4.
8. Aras O, Shet A, Bach RR, Hysjulien JL, Slungaard A, Hebbel RP, Escolar G, Jilma B, Key NS. Induction of microparticle- and cell-associated intravascular tissue factor in human endotoxemia. Blood 2004; 103: 4545-53.
9. Gross PL, Furie BC, Merrill-Skoloff G, Chou J, Furie B. Leukocyte- versus microparticle-mediated tissue factor transfer during arteriolar thrombus development. J Leukocyte Biology 2005; 78: 1318-26.
10. Mandal SK, Pendurthi UR, Rao LV. Cellular localization and trafficking of tissue factor. Blood 2006; 107: 4746-53.
11. Butenas S, Mann KG. Active tissue factor in blood? Nat Med 2004; 10: 1155-6.
12. Osterud B, Bjorklid E. Sources of tissue factor. Semin Thromb Hemost 2006; 32: 11-23.
13. Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989; 86: 2839-43.
14. Hayashi M, Matsushita T, Mackman N, Ito M, Adachi T, Katsumi A, Yamamoto K, Takeshita K, Kojima T, Saito H, Murohara T, Naoe T. Fatal thrombosis of antithrombin-deficient mice is rescued differently in the heart and liver by intercrossing with low tissue factor mice. J Thromb Haemost 2006; 4: 177-85.
15. Pedersen B, Holscher T, Sato Y, Pawlinski R, Mackman N. A balance between tissue factor and tissue factor pathway inhibitor is required for embryonic development and hemostasis in adult mice. Blood 2005; 105: 2777-82.
16. Pawlinski R, Fernandes A, Kehrle B, Pedersen B, Parry G, Erlich J, Pyo R, Gutstein D, Zhang J, Castellino F, Melis E, Carmeliet P, Baretton G, Luther T, Taubman M, Rosen E, Mackman N. Tissue factor deficiency causes cardiac fibrosis and left ventricular dysfunction. Proc Natl Acad Sci USA 2002; 99: 15333-8.
17. Contrino J, Hair G, Kreutzer DL, Rickles FR. In situ detection of tissue factor in vascular endothelial cells: Correlation with the malignant phenotype of human breast disease. Nat Med 1996; 2: 209-15.
18. Osterud B. Tissue factor expression by monocytes: Regulation and pathophysiological roles. Blood Coagul Fibrinolysis 1998; 9 (Suppl. 1): 9-14.
19. Eilertsen KE, Osterud B. Tissue factor: (patho)physiology and cellular biology. Blood Coagul Fibrinolysis 2004; 15: 521-38.
20. Mandal SK, Iakhiaev A, Pendurthi UR, Rao LV. Acute cholesterol depletion impairs functional expression of tissue factor in fibroblasts: modulation of tissue factor activity by membrane cholesterol. Blood 2005; 105: 153-60.
21. Bach RR. Tissue factor encryption. Arterioscler Thromb Vasc Biol 2006; 26: 456-61.
22. Ozcan M, Morton CT, Solovey A, Dandelet L, Bach RR, Hebbel RP, Slungaard A, Key NS. Whole blood tissue factor procoagulant activity remains detectable during severe aplasia following bone marrow and peripheral blood stem cell transplantation. Thromb Haemost 2001; 85: 250-5.
23. Key NS, Slungaard A, Dandelet L, Nelson SC, Moertel C, Styles LA, Kuypers FA, Bach RR. Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood 1998; 91: 4216-23.
24. Giesen PL, Nemerson Y. Tissue factor on the loose. Semin Thromb Hemost 2000; 26: 379-84.
25. Doshi SN, Marmur JD. Evolving role of tissue factor and its pathway inhibitor. Crit Care Med 2002; 30 (Suppl.): S241-50.
26. Llorentes-Cortes V, Otero-Vinas M, Camino-Lopez S, Llampayas O, Badimon L. Aggregated low-density lipoprotein uptake induces membrane tissue factor procoagulant activity and microparticle release in human vascular smooth muscle cells. Circulation 2004; 110: 452-9.
27. Kushak RI, Nestoridi E, Lambert J, Selig MK, Ingelfinger JR, Grabowski EF. Detached endothelial cells and microparticles as sources of tissue factor activity. Thromb Res 2005; 116: 409-19.
28. Tan KT, Lip GY. Platelet microparticles and platelet adhesion: therapeutic implications for the prevention and treatment of stroke. Curr Treat Options Cardiovasc Med 2006; 8: 251-8.
29. Bogdanov VY, Balasubramanian V, Hathcock J, Vele O, Lieb M, Nemerson Y. Alternatively spliced human tissue factor: A circulating, soluble, thrombogenic protein. Nat Med 2003; 9: 458-62.
30. Szotowski B, Antoniak S, Poller W, Schultheiss HP, Rauch U. Procoagulant soluble tissue factor is released from endothelial cells in response to inflammatory cytokines. Circ Res 2005; 96: 1233-9.
31. Hagen FS, Gray CL, O'Hara P, Grant FJ, Saari GC, Woodbury RG, Hart CE, Insley M, Kisiel W, Kurachi K, Davie EW. Characterization of a cDNA coding for human factor VII. Proc Natl Acad Sci USA 1986; 83: 2412-6.
32. Leytus SP, Foster DC, Kurachi K, Davie EW. Gene for human factor X: A blood coagulation factor whose gene organization is essentially identical with that of factor IX and protein C. Biochemistry 1986; 25: 5098-102.
33. Persson E. Macromolecular substrate affinity for free factor VIIa is independent of a buried protease domain N-terminus. Biochem Biophys Res Commun 2006; 341: 28-32.
34. Huang X, Ding WQ, Vaught JL, Wolf RF, Morrissey JH, Harrison RG, Lind SE. A soluble tissue factor-annexin V chimeric protein has both procoagulant and anticoagulant properties. Blood 2006; 107: 980-6.
35. Banner DW, D'Arcy A, Chene C, Winkler FK, Guha A, Konigsberg WH, Nemerson Y, Kirchhofer D. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature 1996; 380: 41-6.
36. Dickinson CD, Ruf W. Active site modification of factor VIIa affects interactions of the protease domain with tissue factor. J Biol Chem 1997; 272: 19875-9.
37. Zhang E, St Charles R, Tulinsky A. Structure of extracellular tissue factor complexed with factor VIIa inhibited with a BPTI mutant. J Mol Biol 1999; 285: 2089-104.
38. Persson E, Nielsen LS, Olsen OH, Aronovitz M, Benjamin C, Hsu YM, Sajer SA, Furie B. Substitution of aspartic acid for methionine-306 in factor VIIa abolishes the allosteric linkage between the active site and the binding interface with tissue factor. Biochemistry 2001; 40: 3251-6.
39. Rand KD, Jorgensen TJ, Olsen OH, Persson E, Jensen ON, Stennicke HR, Andersen MD. The allosteric activation of coagulation factor VIIa visualized by hydrogen exchange. J Biol Chem 2006; 281: 23018-24.
40. Eigenbrot C, Kirchhofer D, Dennis MS, Santell L, Lazarus RA, Stamos J, Ultsch MH. The factor VII zymogen structure reveals reregistration of β strand during activation. Structure 2001; 9: 627-36.
41. Persson E, Bak H, Ostergaard A, Olsen OH. Augmented intrinsic activity of Factor VIIa by replacement of residues 305, 314, 337 and 374: evidence of two unique mutational mechanisms of activity enhancement. Biochem J 2004; 379: 497-503.
42. Bom VJ, Bertina RM. The contributions of Ca2+, phospholipids and tissue-factor apoprotein to the activation of human blood-coagulation factor X by activated factor VII. Biochem J 1990; 265: 327-36.
43. McCallum CD, Hapak RC, Neuenschwander PF, Morrissey JH, Johnson AE. The location of the active site of blood coagulation factor VIIa above the membrane surface and its reorientation upon association with tissue factor. A fluorescence energy transfer study. J Biol Chem 1996; 8: 28168-75.
44. McCallum CD, Su B, Neuenschwander PF, Morrissey JH, Johnson AE. Tissue factor positions and maintains the factor VIIa active site far above the membrane surface even in the absence of the factor VIIa Gla domain. A fluorescence resonance energy transfer study. J Biol Chem 1997; 272: 30160-6.
45. Waters EK, Yegneswaran S, Morrissey JH. Raising the active site of factor VIIa above the membrane surface reduces its procoagulant activity but not factor VII autoactivation. J Biol Chem 2006; 281: 26062-8.
46. Waters EK, Morrissey JH. Restoring full biological activity to the isolated ectodomain of an integral membrane protein. Biochemistry 2006; 45: 3769-74.
47. Wildgoose P, Jorgensen T, Komiyama Y, Nakagaki T, Pedersen A, Kisiel W. The role of phospholipids and the factor VII Gla-domain in the interaction of factor VII with tissue factor. Thromb Haemost 1992; 67: 679-85.
48. Venkateswarlu D, Duke RE, Perera L, Darden TA, Pedersen LG. An all-atom solution-equilibrated model for human extrinsic blood coagulation complex (sTF-VIIa-Xa): A protein-protein docking and molecular dynamics refinement study. J Thromb Haemost 2003; 1: 2577-88.
49. Norledge BV, Petrovan RJ, Ruf W, Olson AJ. The tissue factor/factor VIIa/ factor Xa complex: A model built by docking and site-directed mutagenesis. Proteins 2003; 53: 640-8.
50. Baugh RJ, Dickinson CD, Ruf W, Krishnaswamy S. Exosite interactions determine the affinity of factor X for the extrinsic Xase complex. J Biol Chem 2000; 275: 28826-33.
51. Shobe J, Dickinson CD, Edgington TS, Rud W. Macromolecular substrate affinity for the tissue factor-factor VIIa complex is independent of scissile bond docking. J Biol Chem 1999; 274: 24171-92.
52. Galan AM, Tonda R, Pino M, Reverter JC, Ordinas A, Escolar G. Increased local procoagulant action: A mechanism contributing to the favorable hemostatic effect of recombinant FVIIa in PLT disorders. Transfusion 2003; 43: 885-92.
53. Hoffman M, Monroe DM. A cell-based model of hemostasis. Thromb Hemost 2001; 85: 958-65.
54. Lisman T, Adelmeijer J, Cauwenberghs S, Van Pampus EC, Heemskerk JW, De Groot PG. Recombinant factor VIIa enhances platelet adhesion and activation under flow conditions at normal and reduced platelet count. J Thromb Haemost. 2005; 3: 742-51.
55. Monroe DM, Hoffman M, Oliver JA, Roberts HR. A possible mechanism of action of activated factor VII independent of tissue factor. Blood Coagul Fibrinolysis 1998; 9 (Suppl. 1): S15-20.
56. Hoffman M, Whinna HC, Monroe DM. Circulating tissue factor accumulates in thrombi, but not in hemostatic plugs. J Thromb Haemost 2006; 4: 2092-3.
57. Hrachovinova I, Cambien B, Hafez-Moghadam A, Kappelmeyer J, Camphausen RT, Widom A, Xia L, Kazazian HH Jr, Schaub RG, McEver RP, Wagner DD. Interaction of P-selectin and PSGL-1 generates microparticles that correct hemostasis in a mouse model of hemophilia A. Nat Med 2003; 9: 991-2.
58. Wolberg AS, Allen GA, Monroe DM, Hedner U, Roberts HR, Hoffman M. High dose factor VIIa improves clot structure and stability in a model of haemophilia B. Br J Haematol 2005; 131: 645-55.
59. Carr Jr ME, Alving BM. Effect of fibrin structure on plasmin-mediated dissolution of plasma clots. Blood Coagul Fibrinolysis 1995; 6: 567-73.
60. Henderson N, Key NS, Christie B, Kisiel W, Foster D, Nelsestuen GL. Response of factor VIII and IX-deficient blood to wild type and high membrane affinity mutant factor VIIa in an in.vitro whole blood clotting assay: Possible correlation to clinical outcome. Thromb Haemost 2002; 88: 98-103.
61. Harvey SB, Stone MD, Martinez MB, Nelsestuen GL. Mutagenesis of the gamma-carboxyglutamic acid domain of human factor VII to generate maximum enhancement of the membrane contact site. J Biol Chem 2003; 278: 8363-9.
62. Pike ACW, Brzozowski AM, Roberts SM, Olsen OH, Persson E. Structure of human factor VIIa and its implications for the triggering of blood coagulation. Proc Natl Acad Sci USA 1999; 96: 8925-30.
63. Standeven KF, Grant PJ, Carter AM, Scheiner T, Weisel JW, Ariens RA. Functional analysis of the fibrinogen Aalpha Thr312Ala polymorphism: effects on fibrin structure and function. Circulation 2003; 106: 1938-42.
64. Balasubramanian V, Grabowski E, Bini A, Nemerson Y. Platelets, circulating tissue factor, and fibrin co-localize in ex-vivo thrombi: real-time fluorescence images of thrombus formation and propagation under defined flow conditions. Blood 2002; 100: 2787-92.
65. Hathcock JJ, Nemerson Y. Platelet deposition inhibits tissue factor activity. In.vitro clots are impermeable to factor Xa. Blood 2004; 104: 123-7.
66. Vandendries ER, Furie BC, Furie B. Role of P-selectin and PSGL-1 in coagulation and thrombosis. Thromb Haemost 2004; 92: 459-66.
67. Hartwell DW, Mayadas TN, Berger G, Frenette PS, Rayburn H, Hynes RO, Wagner DD. Role of P-selectin cytoplasmic domain in granular targeting in.vivo and in early inflammatory responses. J Cell Biol 1998; 143: 1129-41.
68. Myers DD, Hawley AE, Farris DM, Wrobleski SK, Thanaporn P, Schaub RG, Wagner DD, Kumar A, Wakefield TW. P-selectin and leukocyte microparticles are associated with venous thrombogenesis. J Vasc Surg 2003; 38: 1075-89.
69. Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation 2001; 103: 491-5.
70. Palabrica T, Lobb R, Furie BC, Aronovitz M, Benjamin C, Hsu YM, Sajer SA, Furie B. Leukocyte accumulation promoting fibrin deposition is mediated in.vivo by P-selectin on adherent platelets. Nature 1992; 359: 848-51.
71. Tsuchihashi S, Fondevila C, Shaw GD, Lorenz M, Marquette K, Benard S, Shen XD, Ke B, Busuttil RW, Kupiec-Weglinski JW. Molecular characterization of rat leukocyte P-selectin glycoprotein ligand-1 and effect of its blockade: Protection from ischemia-reperfusion injury in liver transplantation. J Immunol 2006; 176: 616-24.
72. Cambien B, Wagner DD. A new role in hemostasis for the adhesion receptor P-selectin. Trends Mol Med 2004; 10: 179-86.
73. Dietzen DJ, Page KL, Tetzloff TA. Lipid rafts are necessary for tonic inhibition of cellular tissue factor procoagulant activity. Blood 2004; 103: 3038-44.
74. Chen VM, Ahamed J, Versteeg HH, Berndt MC, Ruf W, Hogg PJ. Evidence for activation of tissue factor by an allosteric disulfide bond. Biochemistry 2006; 45: 12020-8.
75. Ahamed J, Versteeg HH, Kerver M, Chen VM, Mueller BM, Hogg PJ, Ruf W. Disulfide isomerization switches tissue factor from coagulation to cell signaling. Proc Natl Acad Sci USA 2006; 103: 13932-7.
76. Bazan JF. Structural design and molecular evolution of a cytokine receptor superfamily. Proc Nat Acad Sci USA 1990; 87: 6934-8.
77. Schmidt B, Ho L, Hogg PJ. Allosteric disulfide bonds. Biochemistry 2006; 45: 7429-33.
78. Tian G, Xiang S, Noiv R, Lennarz WJ, Schindelin H. The crystal structure of yeast protein disulphide isomerase suggests cooperativity between its active sites. Cell 2006; 124: 61-73.
79. Hathcock JJ. Flow effects on coagulation and thrombosis. Arterioscler Thromb Vasc Biol 2006; 26: 1729-37.
80. Hathcock JJ, Rusinova E, Gentry RD, Andree H, Nemerson. Phospholipid regulates the activation of factor X by tissue factor/factor VIIa (TF/ VIIa) via substrate and product interactions. Biochemistry 2005; 7: 8187-97.
81. Hathcock JJ, Rusinova E, Andree H, Nemerson Y. Phospholipid surfaces regulate the delivery of substrate to tissue factor:VIIa and the removal of product. Blood Cells Mol Dis 2006; 36: 194-8.
82. Broze Jr GJ, Warren LA, Novotny WF, Higuchi DA, Girard JJ, Miletich JP. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: Insight into its possible mechanism of action. Blood 1988; 71: 335-43.
83. Piro O, Broze Jr GJ. Role for the Kunitz-3 domain of tissue factor pathway inhibitor-alpha in cell surface binding. Circulation 2004; 110: 3567-72.
84. Piro O, Broze Jr GJ. Comparison of cell-surface TFPIα and β. J Thromb Haemost 2005; 3: 2677-83.
85. Chang JY, Monroe DM, Oliver JA, Roberts HR. TFPIβ, a second product from the mouse tissue factor pathway inhibitor (TFPI) gene. Thromb Haemost 1999; 81: 45-9.
86. Broze GJ Jr. The tissue factor pathway of coagulation. In: Loscalzo J, Schafer AI, eds. Thrombosis and Hemorrhage. USA: Lippincott Williams & Wilkins, 2003: 70.
87. Sevinsky JR, Rao LV, Ruf W. Ligand-induced protease receptor translocation into caveolae: A mechanism for regulating cell surface proteolysis of the tissue factor-dependent coagulation pathway. J Cell Biol 1996; 133: 293-304.
88. Maroney SA, Cunningham AC, Ferrel J, Hu R, Haberichter S, Mansbach CM, Brodsky RA, Dietzen DJ, Mast AE. A GPI-anchored co-receptor for tissue factor pathway inhibitor controls its intracellular trafficking and cell surface expression. J Thromb Haemost 2006; 4: 1114-24.
89. Lupu C, Poulsen E, Roquefeuil S, Westmuckett AD, Kakkar VV, Lupu F. Cellular effects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture. Arterioscler Thromb Vasc Biol 1999; 19: 2251-62.
90. Baugh RJ, Broze Jr GJ, Krishnaswamy S. Regulation of extrinsic pathway factor Xa formation by tissue factor pathway inhibitor. J Biol Chem 1998; 273: 4378-86.
91. Iakhiaev A, Pendurthi UR, Voigt J, Ezban M, Vijaya Mohan Rao L. Catabolism of factor VIIa bound to tissue factor in fibroblasts in the presence and absence of tissue factor pathway inhibitor. J Biol Chem 1999; 274: 36995-7003.
92. Iakhiaev A, Pendurthi UR, Rao LV. Active site blockade of factor VIIa alters its intracellular distribution. J Biol Chem 2001; 276: 45895-901.
93. Hjortoe G, Sørensen BB, Petersen LC, Rao LV. Factor VIIa binding and internalization in hepatocytes. J Thromb Haemost 2005; 3: 2264-73.
94. Ott I, Miyagi Y, Miyazaki K, Heeb MJ, Mueller BM, Rao LV, Ruf W. Reversible regulation of tissue factor-induced coagulation by glycosylphosphatidylinositol-anchored tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol 2000; 20: 874-82.
95. Docampo R, de Souza W, Miranda K, Rohloff P, Moreno SN. Acidocalcisomes -conserved from bacteria to man. Nat Rev Microbiol 2005; 3: 251-6.
96. Smith SA, Mutch NJ, Baskar D, Rohloff P, Docampo R, Morrissey JH. Polyphosphate modulates blood coagulation and fibrinolysis. PNAS 2006; 103: 903-8.
97. Versteeg HH, Spek CA, Peppelenbosch MP, Richel DJ. Tissue factor and cancer metastasis: The role of intracellular and extracellular signaling pathways. Mol Med 2004; 10: 6-11.
98. Chen VMY, Ruf W, Hogg PJ. Mechanism of activation of tissue factor. J Thromb Haemost 2005; 3 (Suppl. 1): OR075.
99. Camerer E, Rottingen JA, Gjernes E, Larsen K, Skartlien AH, Iversen JG, Prydz H. Coagulation factors VIIa and Xa induce cell signaling leading to the upregulation of the egr-1 gene. J Biol Chem 1999; 274: 32225-33.
100. Versteeg HH, Sørensen BB, Slofstra SH, Van den Brande JH, Stam JC, van Bergen en Henegouwen PM, Richel DJ, Petersen LC, Peppelenbosch MP. VIIa/tissue factor interaction results in a tissue factor cytoplasmic domain-independent activation of protein synthesis, p70 and p90. J Biol Chem 2002; 277: 27065-72.
101. Sørensen BB, Rao LV, Tornehave D, Gammeltoft S, Petersen LC. Antiapoptotic effect of coagulation factor VIIa. Blood 2003; 102: 1708-15.
102. Camerer E, Huang W, Coughlin SR. Tissue factor- and Factor X-dependent activation of PAR2 by factor VIIa. Proc Natl Acad Sci USA 2000; 97: 5255-60.
103. Hjortoe GM, Petersen LC, Albrektsen T, Sorensen BB, Norby PL, Mandal SK, Pendurthi UR, Rao LV. Tissue factor-factor VIIa-specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration. Blood 2004; 103: 3029-37.
104. Versteeg HH, Hoedemaeker I, Diks SH, Stam JC, Spaargaren M, van Bergen En Henegouwen PM, van Deventer SJ, Peppelenbosch MP. Factor VIIa/tissue factor-induced signaling via activation of Src-like kinases, phosphatidylinositol 3-kinase, and Rac. J Biol Chem 2000; 275: 28750-6.
105. Rottingen JA, Enden T, Camerer E, Iversen JG, Prydz H. Binding of human factor VIIa to tissue factor induces cytosolic Ca2+signals in J82 cells, transfected COS-1 cells, Madin-Darby canine kidney cells and in human endothelial cells induced to synthesise tissue factor. J Biol Chem 1995; 270: 4650-60.
106. Camerer E, Rottingen JA, Iverson JG, Prydz H. Coagulation factors VII and X induce Ca2+oscillations in Madin-Darby canine kidney cells only when proteolytically active. J Biol Chem 1996; 271: 29034-42.
107. Poulson LK, Jacobsen N, Sorensen BB, Bergenhem NC, Kelly JD, Foster DC, Thastrup O, Ezban M, Petersen LC. Signal transduction via the mitogen activated protein kinase pathway induced by binding of coagulation factor VIIa to tissue factor. J Biol Chem 1998; 273: 6228-32.
108. Liu Y, Mueller BM. Protease-activated receptor-2 regulates vascular endothelial growth factor expression in MDA-MB-231 cells via MAPK pathways. Biochem Biophys Res Commun 2006; 344: 1263-70.
109. Ruf W, Dorfleutner A, Riewald M. Specificity of coagulation factor signaling. J Thromb Haemost 2003; 1: 1495-503.
110. Ott I, Weigand B, Michl R, Seitz I, Sabbari-Erfani N, Neumann FJ, Schomig A. Tissue factor cytoplasmic domain stimulates migration by activation of the GTPase Rac1 and the mitogen-activated protein kinase p38. Circulation 2005; 111: 349-55.
111. Versteeg HH, Ruf W. Emerging insights into tissue factor-dependent signaling events. Semin Thromb Hemost 2006; 32: 24-32.
112. Belting M, Dorrell MI, Sandgren S, Aguilar E, Ahamed J, Dorfleutner A, Carmeliet P, Mueller BM, Friedlander M, Ruf W. Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med 2004; 10: 502-9.
113. Levi M, van der Poll T, ten Cate H. Tissue factor in infection and severe inflammation. Semin Thromb Hemost 2006; 32: 33-9.
114. Rao LV, Pendurthi UR. Tissue factor-factor VIIa signaling. Arterioscler Thromb Vasc Biol 2005; 25: 47-56.
115. Pawlinski R, Mackman N. Tissue factor, coagulation proteases, and protease-activated receptors in endotoxemia and sepsis. Crit Care Med 2004; 32 (Suppl.): S293-7.
116. Taylor Jr FB, Chang AC, Peer GT, Mather T, Blick K, Catlett R, Lockhart MS, Esmon GT. DEGR-factor Xa blocks disseminated intravascular coagulation initiated by Escherichia coli without preventing shock or organ damage. Blood 1991; 78: 364-8.
117. Camerer E, Cornelissen I, Kataoka H, Duong DN, Zheng YW, Coughlin SR. Roles of protease-activated receptors in a mouse model of endotoxemia. Blood 2006; 107: 3912-21.
118. Andonegui G, Kerfoot SM, McNagny K, Ebbert KV, Patel KD, Kubes P. Platelets express functional Toll-like receptor-4. Blood 2005; 106: 2417-23.
119. Chen D, Weber M, McVey JH, Kemball-Cook G, Tuddenham EG, Lechler RI, Dorling A. Complete inhibition of acute humoral rejection using regulated expression of membrane-tethered anticoagulants on xenograft endothelium. Am J Transplant 2004; 4: 1958-63.